Research programme: brain cancer therapy - BioconAlternative Names: NET-001/002
Latest Information Update: 10 Apr 2007
At a glance
- Originator Biocon
- Mechanism of Action DNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Brain cancer
Most Recent Events
- 01 Apr 2004 This compound is still in active development
- 26 Sep 2002 Preclinical trials in Brain cancer in USA (unspecified route)